Loading...
•
Dec 31, 2021
Co-Diagnostics Q4 2021 Earnings Report
Co-Diagnostics reported record full year revenue driven by innovative product portfolio and ability to adapt to increased demand.
Key Takeaways
Co-Diagnostics reported record full year 2021 revenue of $97.9 million. The company highlighted its strengthened executive management team and advancements in its at-home/point-of-care diagnostics platform.
Achieved record full year revenue, reflecting the strength of the innovative product portfolio.
Strengthened the executive management team with key appointments.
Announced the existence of a new at-home/point-of-care diagnostics platform.
Completed two strategic acquisitions to enhance efficiencies related to the new platform.
Forward Guidance
Co-Diagnostics believes that the demand for its COVID-19 tests and other diagnostic products will persist. The Co-Dx YourTest PCR™ platform, along with the innovative portfolio of tests, provides a strong foundation for 2022.
Positive Outlook
- Demand for COVID-19 tests and other diagnostic products will persist.
- Reputation has now been established and continues to grow among the diagnostic testing community.
- Organizations continue to implement COVID-19 testing as part of normal protocol.
- Focused on long-term strategy.
- Co-Dx YourTest PCR™ platform will contribute to future growth.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...